Cibus, Inc. (CBUS)
NASDAQ: CBUS · IEX Real-Time Price · USD
15.84
+0.30 (1.93%)
At close: Apr 26, 2024, 4:00 PM
16.14
+0.30 (1.89%)
After-hours: Apr 26, 2024, 5:23 PM EDT
Company Description
Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties.
The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Cibus, Inc. is based in San Diego, California.
Cibus, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Rory Balfour Riggs M.B.A. |
Contact Details
Address: 6455 Nancy Ridge Drive San Diego, California 92121 United States | |
| Phone | (858) 450-0008 |
| Website | cibus.com |
Stock Details
| Ticker Symbol | CBUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001705843 |
| ISIN Number | US17166A1016 |
| Employer ID | 27-1967997 |
| SIC Code | 2870 |
Key Executives
| Name | Position |
|---|---|
| Rory Balfour Riggs M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Peter Beetham B.Sc., Ph.D. | Co-Founder, President, Chief Operating Officer and Director |
| Dr. Greg Gocal Ph.D. | Co-Founder, Chief Scientific Officer and Executive Vice President |
| Dr. Wade Hampton King | Chief Financial Officer |
| Jason Stokes J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Rosa Cheuk Kim J.D. | Senior Vice President of Legal |
| Dr. James Radtke Ph.D. | Senior Vice President of Product Development |
| Tony Moran | Senior Vice President of International Development |
| Norm Sissons | Senior Vice President of Seed and Traits |
| Noel Sauer Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 9, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 8-K | Current Report |